动态对比增强MRI影像组学模型预测IDH野生型胶质母细胞瘤的表皮生长因子受体扩增
本研究开发并验证基于动态对比增强(DCE)MRI的影像组学模型,用于预测IDH野生型胶质母细胞瘤患者的表皮生长因子受体(EGFR)扩增状态。纳入2015年1月至2020年12月病理确诊的190例患者,按7:3分为训练集(133例)和测试集(57例)。测试集中,基于Ktrans图的影像组学模型预测EGFR扩增的AUROC最高,为0.80(95%CI 0.65-0.95),高于基于Ve图的0.74(95%CI 0.58-0.90)和基于常规MRI的0.76(95%CI 0.61-0.91)。
要点
- 基于Ktrans图的DCE MRI影像组学模型预测EGFR扩增的AUROC为0.80(95%CI 0.65-0.95)。
- 基于Ve图的模型AUROC为0.74(95%CI 0.58-0.90),基于常规MRI的模型AUROC为0.76(95%CI 0.61-0.91)。
- 基于Ktrans图的影像组学模型AUROC高于基于常规MRI的模型。
核心结论
- 开发并验证了基于DCE MRI的影像组学模型,用于预测IDH野生型胶质母细胞瘤的EGFR扩增。
- 基于Ktrans图的影像组学模型AUROC高于基于常规MRI的模型。
研究设计与样本
- 纳入2015年1月至2020年12月病理确诊的IDH野生型胶质母细胞瘤且有EGFR扩增状态的患者。
- 排除未进行DCE或常规脑MRI的患者。
- 按7:3比例将患者分为训练集和测试集。
- 使用DCE MRI数据生成Ktrans和Ve图,并提取影像组学特征以构建预测模型。
- 共纳入190例患者(平均年龄59.9岁;男性55.3%),训练集133例,测试集57例。
主要发现
- 测试集中,基于Ktrans图的影像组学模型AUROC为0.80(95%CI 0.65-0.95)。
- 测试集中,基于Ve图的模型AUROC为0.74(95%CI 0.58-0.90)。
- 测试集中,基于常规MRI的模型AUROC为0.76(95%CI 0.61-0.91)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop and validate a dynamic contrast-enhanced (DCE) MRI-based radiomics model to predict epidermal growth factor receptor (EGFR) amplification in patients with glioblastoma, isocitrate dehydrogenase (IDH) wildtype. METHODS: Patients with pathologically confirmed glioblastoma, IDH wildtype, from January 2015 to December 2020, with an EGFR amplification status, were included. Patients who did not undergo DCE or conventional brain MRI were excluded. Patients were categorized into training and test sets by a ratio of 7:3. DCE MRI data were used to generate volume transfer constant (Ktrans) and extracellular volume fraction (Ve) maps. Ktrans, Ve, and conventional MRI were then used to extract the radiomics features, from which the prediction models for EGFR amplification status were developed and validated. RESULTS: A total of 190 patients (mean age, 59.9; male, 55.3%), divided into training (n = 133) and test (n = 57) sets, were enrolled. In the test set, the radiomics model using the Ktrans map exhibited the highest area under the receiver operating characteristic curve (AUROC), 0.80 (95% confidence interval [CI], 0.65-0.95). The AUROC for the Ve map-based and conventional MRI-based models were 0.74 (95% CI, 0.58-0.90) and 0.76 (95% CI, 0.61-0.91). CONCLUSION: The DCE MRI-based radiomics model that predicts EGFR amplification in glioblastoma, IDH wildtype, was developed and validated. The MRI-based radiomics model using the Ktrans map has higher AUROC than conventional MRI.
引用
- Sohn B, Park K, Ahn SS, et al. Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype. J Neurooncol. 2023. PMID: 37689596. doi:10.1007/s11060-023-04435-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。